Payment overview · 2025
General Payments
$245.92
13 reported records · 10 companies
Healthcare provider profile · identity verified
Carlos Ermocilla, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAS VEGAS, NV · NPI 1497799407
Verified facts
What the public records show
CMS Open Payments records show Carlos Ermocilla, M.D. received $245.92 in general payments during 2025 across 13 reported records.
Lilly USA, LLC accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.49 | 16.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.43 | 12.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.39 | 12.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $29.15 | 11.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.39 | 11.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.89 | 8.9% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.39 | 8.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.24 | 6.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.65 | 6.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.90 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $245.92 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $52.56 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $29.15 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $21.89 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 76 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 864 | 274 |
| Losartan Potassium | Losartan Potassium | 420 | 134 |
| Metformin Hcl | Metformin Hcl | 420 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 102 |
| Lisinopril | Lisinopril | 327 | 98 |
| Omeprazole | Omeprazole | 306 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 221 | 39 |
| Alprazolam | Alprazolam | 210 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 68 |
| Gabapentin | Gabapentin | 181 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 53 |
| Alendronate Sodium | Alendronate Sodium | 125 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 39 |
| Simvastatin | Simvastatin | 109 | 40 |
| Tramadol Hcl | Tramadol Hcl | 106 | 23 |
| Glipizide Er | Glipizide | 101 | 33 |
| Donepezil Hcl | Donepezil Hcl | 97 | 31 |
| Trazodone Hcl | Trazodone Hcl | 92 | 35 |
| Famotidine | Famotidine | 88 | 36 |
| Furosemide | Furosemide | 86 | 36 |
| Allopurinol | Allopurinol | 80 | 24 |
| Eliquis | Apixaban | 76 | 20 |
| Glipizide | Glipizide | 76 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 40 |
| Carvedilol | Carvedilol | 71 | 27 |
| Ibuprofen | Ibuprofen | 71 | 29 |
| Sertraline Hcl | Sertraline Hcl | 71 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 23 |
| Lovastatin | Lovastatin | 67 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 19 |
| Cefdinir | Cefdinir | 60 | 51 |
| Glimepiride | Glimepiride | 57 | 22 |
| Montelukast Sodium | Montelukast Sodium | 56 | 22 |
| Jardiance | Empagliflozin | 55 | 19 |
| Temazepam | Temazepam | 55 | suppressed |
| Clonazepam | Clonazepam | 54 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 18 |
| Januvia | Sitagliptin Phosphate | 53 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 21 |
| Prednisone | Prednisone | 49 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 16 |
| Ozempic | Semaglutide | 44 | suppressed |
| Atenolol | Atenolol | 43 | 14 |
| Azithromycin | Azithromycin | 43 | 34 |
| Finasteride | Finasteride | 41 | 16 |
| Meloxicam | Meloxicam | 41 | 15 |
| Memantine Hcl | Memantine Hcl | 40 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 15 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Naproxen | Naproxen | 31 | 13 |
| Valsartan | Valsartan | 31 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 23 |
| Humulin N | Insulin Nph Human Isophane | 30 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Potassium Chloride | Potassium Chloride | 27 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 24 | suppressed |
| Repatha Syringe | Evolocumab | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Cephalexin | Cephalexin | 12 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $245.92 · 13 records | Lilly USA, LLC | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Flexitouch Plus, JARDIANCE, KISUNLA, NURTEC ODT, Nimbl, OTEZLA, REPATHA, REXULTI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error